{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:56:04Z","timestamp":1782341764535,"version":"3.54.5"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early-onset preeclampsia (EOPE) is associated with placental malperfusion and systemic endothelial dysfunction. Maternal immune dysregulation has been implicated in EOPE, but immune findings obtained during severe disease are descriptive and do not define a validated EOPE subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 22-year-old woman (G2P0) with a monochorionic diamniotic twin pregnancy developed gestational hypertension at 25\n                      <jats:sup>+5<\/jats:sup>\n                      weeks and met criteria for EOPE at 30\u201331 weeks. Because of refractory progression under standard management, immune testing obtained at 31\n                      <jats:sup>+1<\/jats:sup>\n                      weeks showed elevated TNF-\u03b1, low complement C4, weak ANA positivity, and T\/B-cell imbalance (descriptive findings in this single case). After multidisciplinary discussion and informed consent for off-label therapy in pregnancy, an immunomodulatory regimen was started at 31\n                      <jats:sup>+1<\/jats:sup>\n                      weeks (prednisone 10 mg\/day, hydroxychloroquine 200 mg bid, and a single 200 mg SC dose of certolizumab pegol). Over the subsequent week, proteinuria decreased by &amp;gt;50% (10.78 to 4.99 g\/24 h), blood pressure improved to 100\u2013120\/60\u201380 mmHg, and edema regressed. Gestation continued until 35\n                      <jats:sup>+0<\/jats:sup>\n                      weeks, when cesarean delivery was performed for fetal compromise (Type II sFGR with umbilical-artery AEDF). Placental pathology showed multifocal infarctions and basal-plate fibrinoid deposition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>EOPE likely involves heterogeneous pathways in which inflammatory mediators, complement dysregulation, and cytokine excess have been reported. This case is hypothesis-generating and highlights the need for validated immune\/angiogenic stratification and prospective evaluation of any adjunctive immunomodulatory approach in severe EOPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single MCDA twin pregnancy complicated by severe EOPE and concurrent immune-activation markers, initiation of a pregnancy-compatible immunomodulatory regimen was temporally associated with maternal clinical stabilization and a 3\u20134-week interval to delivery for fetal indications. Controlled studies with validated phenotyping, serial biomarkers (including sFlt-1\/PlGF), standardized endpoints, and detailed safety follow-up are needed before attributing benefit or recommending this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1742646","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:09Z","timestamp":1773120669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune profiling-informed immunomodulation associated with gestational extension in early-onset preeclampsia with monochorionic twins: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Dengqin","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First People\u2019s Hospital of Tianshui","place":["Tianshui, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyan","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First People\u2019s Hospital of Tianshui","place":["Tianshui, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Guang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First People\u2019s Hospital of Tianshui","place":["Tianshui, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030154","article-title":"Understanding preeclampsia: cardiovascular pathophysiology, histopathological insights and molecular biomarkers","volume":"13","author":"Kutllovci Hasani","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147569","article-title":"A narrative review on the pathophysiology of preeclampsia","volume":"25","author":"Torres-Torres","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01864","article-title":"Mechanisms of key innate immune cells in early- and late-onset preeclampsia","volume":"11","author":"Aneman","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2147\/rmhp.S304040","article-title":"A review of research progress of pregnancy with twins with preeclampsia","volume":"14","author":"Wang","year":"2021","journal-title":"Risk Manag Healthc Policy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51512","article-title":"The management of preeclampsia: A comprehensive review of current practices and future directions","volume":"16","author":"Sharma","year":"2024","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e081610","DOI":"10.1136\/bmjopen-2023-081610","article-title":"Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study)","volume":"14","author":"Kim","year":"2024","journal-title":"BMJ Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of\u00a0placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01659","article-title":"Disruption in the regulation of immune responses in the placental subtype of preeclampsia","volume":"9","author":"Geldenhuys","year":"2018","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115314","article-title":"Immunological dysregulation in preeclampsia: Pathogenesis and clinical implications","volume":"163","author":"Qin","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00670-0","article-title":"The role of immune cells and mediators in preeclampsia","volume":"19","author":"Deer","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.004","article-title":"Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy","volume":"82","author":"Collier","year":"2021","journal-title":"Hum Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245722","article-title":"The complement system, T cell response, and cytokine shift in normotensive versus pre-eclamptic and lupus pregnancy","volume":"10","author":"Ancu\u0163a","year":"2021","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2025.153014","article-title":"Eculizumab in severe HELLP syndrome \u2013 a case report","volume":"230","author":"Korkalainen","year":"2025","journal-title":"Immunobiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014746","article-title":"Complement C5 inhibition in early onset HELLP syndrome","volume":"9","author":"Gerber","year":"2025","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.preghy.2021.02.006","article-title":"The role of tumor necrosis factor in triggering activation of natural killer cell, multi-organ mitochondrial dysfunction and hypertension during pregnancy","volume":"24","author":"Jayaram","year":"2021","journal-title":"Pregnancy Hypertension"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140189","article-title":"Pregnancy outcomes in subjects exposed to certolizumab pegol","volume":"42","author":"Clowse","year":"2015","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.012","article-title":"Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial","volume":"84","author":"Branch","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000003747","article-title":"TNF-\u03b1 inhibitor use during pregnancy and the risk of preeclampsia: population-based cohort study","volume":"42","author":"Adomi","year":"2024","journal-title":"J Hypertens"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003880","article-title":"Tumor necrosis factor-\u03b1 inhibitors and preeclampsia: assessing the evidence for risk reduction","volume":"43","author":"Tang","year":"2025","journal-title":"J Hypertension"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.42793","article-title":"Hydroxychloroquine in lupus pregnancy and risk of preeclampsia","volume":"76","author":"Rector","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25386","article-title":"Hydroxychloroquine and pre-eclampsia in a diverse cohort of women with systemic lupus erythematosus","volume":"76","author":"Simard","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(25)00076-1","article-title":"Exposure to hydroxychloroquine in early pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study","volume":"7","author":"Nguyen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e001239","DOI":"10.1136\/lupus-2024-001239","article-title":"Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.09.002","article-title":"Hydroxychloroquine in systemic lupus erythematosus, anti-SSA\/SSB, and antiphospholipid antibody-positive pregnancies","volume":"234","author":"Saleh","year":"2025","journal-title":"Am J Obstetrics Gynecology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e000651","DOI":"10.1136\/lupus-2021-000651","article-title":"Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data","volume":"9","author":"Clowse","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00548","article-title":"Eculizumab treatment for postpartum HELLP syndrome and aHUS-case report","volume":"11","author":"Lokki","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2019.08.028","article-title":"Apheresis as emerging treatment option in severe early onset preeclampsia","volume":"40","author":"Contini","year":"2019","journal-title":"Atheroscl Suppl"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadhani","year":"2011","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/uog.28001","article-title":"OP16.01: *Incidence and risk of pre-eclampsia n twins according to gestational age, chorionicity, zygosity, and gender: a nationwide Danish study","volume":"7","author":"Kristensen","year":"2025","journal-title":"Am J Obstet Gynecol MFM"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2025.101760","article-title":"First-trimester combined screening for preeclampsia in twin pregnancies\u2014results of the first 100 twin pregnancies included in the IPSISS (Implementing Preeclampsia Screening in Switzerland) cohort","volume":"7","author":"Monod","year":"2025","journal-title":"Am J Obstet Gynecol MFM"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/FM9.0000000000000076","article-title":"Complications of monochorionic diamniotic twins: stepwise approach for early identification, differential diagnosis, and clinical management","volume":"3","author":"Micheletti","year":"2021","journal-title":"Maternal-Fetal Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18203\/2394-6040.ijcmph20244057","article-title":"Case report on monochorionic diamniotic twins with gestational\u00a0hypertension","volume":"12","author":"Amin","year":"2024","journal-title":"Int J Community Med Public Health"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ph17070904","article-title":"Pregnancy recommendations solely based on preclinical evidence should be integrated with real-world evidence: A disproportionality analysis of certolizumab and other TNF-alpha inhibitors used in pregnant patients with psoriasis","volume":"17","author":"Gaio","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/acr2.70117","article-title":"Tumor necrosis factor inhibitors and risk of serious infections in pregnant women with chronic inflammatory diseases","volume":"7","author":"Flatman","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/03009742.2024.2303832","article-title":"Tumour necrosis factor inhibitors and serious infections in reproductive-age women and their offspring: a narrative review","volume":"53","author":"Flatman","year":"2024","journal-title":"Scand J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:10Z","timestamp":1773120670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1742646"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1742646","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1742646"}}